The first major study of an experimental vaccine to prevent cervical cancer found it was 100 percent effective, in the short term, at blocking the disease and lesions likely to turn cancerous, drug maker Merck & Co said.
Gardasil, a genetically engineered vaccine, blocks infection with two of the 100-plus types of human papilloma virus, HPV 16 and 18. The two sexually transmitted viruses together cause about 70 percent of cervical cancers.
Our 2024 Coverage Needs You
Support HuffPost
Already contributed? Log in to hide these messages.